Currently, combinations strategies that include IFN-α/β appear to be the most promising immunomodulating approaches for the treatment of hematologic malignancies, such as those combining JAK2 inhibitors with IFN-α/β for MPN, with a real possibility of inducing long-term remissions. This evidence concerns the gene JAK2 and hematologic disorder.